Dianthus Therapeutics, Inc. /DE/ - Common Stock (DNTH)
CUSIP: 252828108
Q3 2023 13F Holders as of 30 Sep 2023
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 51,647,137
- Total 13F shares
- 10,072,640
- Share change
- +10,072,640
- Total reported value
- $136,328,208
- Price per share
- $13.67
- Number of holders
- 30
- Value change
- +$136,328,208
- Number of buys
- 30
Quarterly Holders Quick Answers
What is CUSIP 252828108?
CUSIP 252828108 identifies DNTH - Dianthus Therapeutics, Inc. /DE/ - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Newer quarter: Q4 2023
Recent filing periods for CUSIP 252828108:
Top shareholders of DNTH - Dianthus Therapeutics, Inc. /DE/ - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Third Rock Ventures IV, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,058,204
|
$36,698,448 | — | 07 Feb 2023 | |
| Jason Gardner |
3/4/5
|
Title: President and Chief Executive Officer, Director |
—
class O/S missing
|
944,954
|
$11,339,448 | — | 30 Nov 2022 | |
| Kristen Stants |
3/4/5
|
Chief People Officer |
—
class O/S missing
|
20,264
|
$243,168 | — | 30 Nov 2022 | |
| Thomas W. Beetham |
3/4/5
|
Title: Chief Legal Officer and Secretary |
—
class O/S missing
|
19,897
|
$238,764 | — | 30 Nov 2022 | |
| Caren Deardorf |
3/4/5
|
Chief Commercial Officer |
—
class O/S missing
|
19,762
|
$237,144 | — | 30 Nov 2022 | |
| Stephen F. Mahoney |
3/4/5
|
Title: Chief Financial and Operating Officer |
—
class O/S missing
|
17,264
|
$207,168 | — | 30 Nov 2022 | |
| Alexis Borisy |
3/4/5
|
Director |
—
class O/S missing
|
4,100
|
$49,200 | — | 26 Aug 2021 | |
| Lisa Olson |
3/4/5
|
Title: Head of Research and Chief Scientific Officer Exhibit 24.1: Power of Attorney |
—
class O/S missing
|
100,000
|
— | — | 01 Aug 2022 | |
| David Wayne Nichols |
3/4/5
|
Chief Technical Officer |
—
class O/S missing
|
75,000
|
— | — | 01 Aug 2022 | |
| Jeffrey Humphrey |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
75,000
|
— | — | 01 Aug 2022 | |
| Michael Vasconcelles |
3/4/5
|
Director |
—
class O/S missing
|
40,000
|
— | — | 15 Aug 2022 | |
| Amy L. Ronneberg |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 28 Jun 2022 | |
| Bruce Booth |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 28 Jun 2022 | |
| Daniel Thomas O |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 28 Jun 2022 | |
| David Scadden |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 28 Jun 2022 | |
| Jeffrey W. Albers |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 28 Jun 2022 | |
| Michael W. Bonney |
3/4/5
|
Director |
—
class O/S missing
|
18,188
|
— | — | 01 Jun 2021 |
Institutional Holders of Dianthus Therapeutics, Inc. /DE/ - Common Stock (DNTH) as of Q3 2023
As of 30 Sep 2023,
Dianthus Therapeutics, Inc. /DE/ - Common Stock (DNTH) was held by
30 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
10,072,640 shares.
The largest 10 holders included
FMR LLC, Fairmount Funds Management LLC, 5AM Venture Management, LLC, Avidity Partners Management LP, VR Adviser, LLC, TANG CAPITAL MANAGEMENT LLC, Octagon Capital Advisors LP, Nantahala Capital Management, LLC, Atlas Venture Life Science Advisors, LLC, and Alphabet Inc..
This page lists
30
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2023 vs Q4 2025 Across Filers
Q4 2025 holders
167
Q3 2023 holders
30
Holder diff
-137
| Investor | Q4 2025 Shares | Q3 2023 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q3 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.